DelveInsight’s ‘Chronic Pulmonary Hypertension Market Insights, Epidemiology and Market Forecast—2032’ report deliver an in-depth understanding of Chronic Pulmonary Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Chronic Pulmonary Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chronic Pulmonary Hypertension symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Chronic Pulmonary Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Chronic Pulmonary Hypertension Market:
- The secondary research on the growth rate by analysts at DelveInsight across the 7MM population for CPH states that in the US the growth rate of the CPH patient pool in the forecast period (2022-2032) is 0.78%. The EU-5 on the other hand reports a population growth rate of 0.18%.
- CPH has a significant prevalence among the old population. Secondary findings show that the US has 17,363,064 of total prevalent cases of PH in 2019.
- Group-based CPH prevalence is divided into four main parts: Group 1, Group 2, Group 3, and Group 4. The most common group of CPH patients is Group 2 CPH (i.e., PH associated with left heart disease). It is estimated that approximately 3-4 million adults in the United States have Group 2 CPH.
Got queries? Click here to know more about the Chronic Pulmonary Hypertension Market Landscape
Chronic Pulmonary Hypertension Overview
Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. Pulmonary hypertension is a progressive disease with treatment focused on the management of symptoms and treatment of underlying diseases. Some common underlying causes of pulmonary hypertension include high blood pressure in the lungs’ arteries due to some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases like emphysema. Genetics also plays a role.
Pulmonary hypertension can happen in association with many other diseases, such as lung disease and heart disease. Heart failure is common in pulmonary hypertension.
The symptoms of pulmonary hypertension during the initial stage of the disease are common to many other medical conditions (e.g., difficulty breathing, and fatigue). This often results in a delayed diagnosis until more severe symptoms arise, such as dizziness, chest pain, ankle swelling, or feeling the heart race or pound (palpitations).
Chronic Pulmonary Hypertension Epidemiological Insight:
- Corris & Seeger (2020) found that the true global burden of pulmonary hypertension is not yet known, but it is certainly underestimated. It should no longer be considered as a rare disease and, for several important reasons, its impact on global health needs to be urgently assessed.
- World Health Organization (WHO) has organized PH into 5 classifications according to the cause, and classifications. Group 1 primary pulmonary hypertension, or pulmonary arterial hypertension (PAH). Among this group, idiopathic PAH is the most common condition, with other causes such as toxin-induced, connective tissue disorders, and other related conditions being less prevalent. Group 2 involves PH due to left heart disease, which is the most common cause of PH. Group 3 PH is due to lung diseases such COPD and interstitial lung disease. Chronic pulmonary thromboembolism causes group 4 PH, and group 5 PH is due to unclear or multifactorial causes
- According to Secondary Research by analysts at DelveInsight, PH includes a variety of diseases classified according to its etiology and hemodynamic profile. Gender differences are observed in practically all groups of PH. Females present a higher risk of disease development as compared to males
Chronic Pulmonary Hypertension Epidemiological Segmentation
- Chronic Pulmonary Hypertension Total prevelant cases
- Chronic Pulmonary Hypertension Age specific cases
- Chronic Pulmonary Hypertension Diagnosed and Treatable cases
Chronic Pulmonary Hypertension Market Outlook
The Pulmonary Hypertension market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Hypertension market trends by analyzing the impact of current Pulmonary Hypertension therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Pulmonary Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pulmonary Hypertension market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Pulmonary Hypertension market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @Chronic Pulmonary Hypertension Market Landscape
Chronic Pulmonary Hypertension Key Companies
- Attgeno AB
- Cereno Scientific AB
- Bial – Portela C S.A.
- Liquidia Technologies
- And many more
Chronic Pulmonary Hypertension Key Therapies
- Supernitro
- CS1
- Zamicastat (BIA 5-1058)
- Yutrepia (LIQ861 Inhaled Treprostinil)
- And many more
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Chronic Pulmonary Hypertension Market
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Chronic Pulmonary Hypertension Market Emerging Therapies
- Chronic Pulmonary Hypertension Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Chronic Pulmonary Hypertension Market Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Chronic Pulmonary Hypertension Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com